APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drug-Device Combination Products

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Drug-Device Combination Products Market Analysis and Forecast 2026-2032

20 December 2025215 pages

Choose your research edition.

Industry ResearchDrug-Device Combination Products Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Drug-Device Combination Products Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Drug-Device Combination Products Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drug-Device Combination Products Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal Drug-Device Combination Products Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Drug-Device Combination Products market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Drug-Device Combination Products is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Drug-Device Combination Products is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Drug-Device Combination Products is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Drug-Device Combination Products is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Drug-Device Combination Products include GSK, Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi, Boston Scientific, Abbott, Boehringer Ingelheim and Medtronic, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Drug-Device Combination Products, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Drug-Device Combination Products, also provides the revenue of main regions and countries. Of the upcoming market potential for Drug-Device Combination Products, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Drug-Device Combination Products revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Drug-Device Combination Products market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Drug-Device Combination Products revenue, projected growth trends, production technology, application and end-user industry.

Drug-Device Combination Products Segment by Company

GSK

Novo Nordisk

Eli Lilly

AstraZeneca

Sanofi

Boston Scientific

Abbott

Boehringer Ingelheim

Medtronic

Mylan

3M

Hisamitsu

Smith & Nephew

Molnlycke

Teleflex

BD

Lepu Medical

MicroPort

Terumo

B. Braun

Antares Pharma

Drug-Device Combination Products Segment by Type

Drug-Coated Device

Prefilled Drug Delivery Systems

Nebulizer and Inhaler

Transdermal Delivery System

Others

Drug-Device Combination Products Segment by Application

Hospital andClinic

Retail Pharmacies

Other

Drug-Device Combination Products Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drug-Device Combination Products market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drug-Device Combination Products and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drug-Device Combination Products.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Drug-Device Combination Products in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Drug-Device Combination Products company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drug-Device Combination Products revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Drug-Device Combination Products Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Drug-Coated Device Major Player Table 3. Prefilled Drug Delivery Systems Major Player Table 4. Nebulizer and Inhaler Major Player Table 5. Transdermal Delivery System Major Player Table 6. Others Major Player Table 7. Global Drug-Device Combination Products Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospital andClinic Major Player Table 9. Retail Pharmacies Major Player Table 10. Other Major Player Table 11. Drug-Device Combination Products Industry Trends Table 12. Drug-Device Combination Products Industry Drivers Table 13. Drug-Device Combination Products Industry Opportunities and Challenges Table 14. Drug-Device Combination Products Industry Restraints Table 15. Global Drug-Device Combination Products Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Drug-Device Combination Products Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Drug-Device Combination Products Market Share by Region (2021-2026) Table 18. Global Drug-Device Combination Products Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Drug-Device Combination Products Market Share by Region (2027-2032) Table 20. Global Drug-Device Combination Products Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Drug-Device Combination Products Revenue Market Share by Players (2021-2026) Table 22. Global Drug-Device Combination Products Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Drug-Device Combination Products Key Players Headquarters & Area Served Table 24. Global Drug-Device Combination Products Players, Product Type & Application Table 25. Global Drug-Device Combination Products Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Drug-Device Combination Products by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Drug-Device Combination Products Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Drug-Device Combination Products Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Drug-Device Combination Products Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Drug-Device Combination Products Revenue Market Share by Type (2021-2026) Table 32. Global Drug-Device Combination Products Revenue Market Share by Type (2027-2032) Table 33. Global Drug-Device Combination Products Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Drug-Device Combination Products Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Drug-Device Combination Products Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Drug-Device Combination Products Revenue Market Share by Application (2021-2026) Table 37. Global Drug-Device Combination Products Revenue Market Share by Application (2027-2032) Table 38. GSK Company Information Table 39. GSK Business Overview Table 40. GSK Drug-Device Combination Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. GSK Drug-Device Combination Products Product Portfolio Table 42. GSK Recent Development Table 43. Novo Nordisk Company Information Table 44. Novo Nordisk Business Overview Table 45. Novo Nordisk Drug-Device Combination Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Novo Nordisk Drug-Device Combination Products Product Portfolio Table 47. Novo Nordisk Recent Development Table 48. Eli Lilly Company Information Table 49. Eli Lilly Business Overview Table 50. Eli Lilly Drug-Device Combination Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Eli Lilly Drug-Device Combination Products Product Portfolio Table 52. Eli Lilly Recent Development Table 53. AstraZeneca Company Information Table 54. AstraZeneca Business Overview Table 55. AstraZeneca Drug-Device Combination Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. AstraZeneca Drug-Device Combination Products Product Portfolio Table 57. AstraZeneca Recent Development Table 58. Sanofi Company Information Table 59. Sanofi Business Overview Table 60. Sanofi Drug-Device Combination Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Sanofi Drug-Device Combination Products Product Portfolio Table 62. Sanofi Recent Development Table 63. Boston Scientific Company Information Table 64. Boston Scientific Business Overview Table 65. Boston Scientific Drug-Device Combination Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Boston Scientific Drug-Device Combination Products Product Portfolio Table 67. Boston Scientific Recent Development Table 68. Abbott Company Information Table 69. Abbott Business Overview Table 70. Abbott Drug-Device Combination Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Abbott Drug-Device Combination Products Product Portfolio Table 72. Abbott Recent Development Table 73. Boehringer Ingelheim Company Information Table 74. Boehringer Ingelheim Business Overview Table 75. Boehringer Ingelheim Drug-Device Combination Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Boehringer Ingelheim Drug-Device Combination Products Product Portfolio Table 77. Boehringer Ingelheim Recent Development Table 78. Medtronic Company Information Table 79. Medtronic Business Overview Table 80. Medtronic Drug-Device Combination Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Medtronic Drug-Device Combination Products Product Portfolio Table 82. Medtronic Recent Development Table 83. Mylan Company Information Table 84. Mylan Business Overview Table 85. Mylan Drug-Device Combination Products Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Mylan Drug-Device Combination Products Product Portfolio Table 87. Mylan Recent Development Table 88. 3M Company Information Table 89. 3M Business Overview Table 90. 3M Drug-Device Combination Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. 3M Drug-Device Combination Products Product Portfolio Table 92. 3M Recent Development Table 93. Hisamitsu Company Information Table 94. Hisamitsu Business Overview Table 95. Hisamitsu Drug-Device Combination Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Hisamitsu Drug-Device Combination Products Product Portfolio Table 97. Hisamitsu Recent Development Table 98. Smith & Nephew Company Information Table 99. Smith & Nephew Business Overview Table 100. Smith & Nephew Drug-Device Combination Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Smith & Nephew Drug-Device Combination Products Product Portfolio Table 102. Smith & Nephew Recent Development Table 103. Molnlycke Company Information Table 104. Molnlycke Business Overview Table 105. Molnlycke Drug-Device Combination Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Molnlycke Drug-Device Combination Products Product Portfolio Table 107. Molnlycke Recent Development Table 108. Teleflex Company Information Table 109. Teleflex Business Overview Table 110. Teleflex Drug-Device Combination Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Teleflex Drug-Device Combination Products Product Portfolio Table 112. Teleflex Recent Development Table 113. BD Company Information Table 114. BD Business Overview Table 115. BD Drug-Device Combination Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. BD Drug-Device Combination Products Product Portfolio Table 117. BD Recent Development Table 118. Lepu Medical Company Information Table 119. Lepu Medical Business Overview Table 120. Lepu Medical Drug-Device Combination Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Lepu Medical Drug-Device Combination Products Product Portfolio Table 122. Lepu Medical Recent Development Table 123. MicroPort Company Information Table 124. MicroPort Business Overview Table 125. MicroPort Drug-Device Combination Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. MicroPort Drug-Device Combination Products Product Portfolio Table 127. MicroPort Recent Development Table 128. Terumo Company Information Table 129. Terumo Business Overview Table 130. Terumo Drug-Device Combination Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Terumo Drug-Device Combination Products Product Portfolio Table 132. Terumo Recent Development Table 133. B. Braun Company Information Table 134. B. Braun Business Overview Table 135. B. Braun Drug-Device Combination Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. B. Braun Drug-Device Combination Products Product Portfolio Table 137. B. Braun Recent Development Table 138. Antares Pharma Company Information Table 139. Antares Pharma Business Overview Table 140. Antares Pharma Drug-Device Combination Products Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Antares Pharma Drug-Device Combination Products Product Portfolio Table 142. Antares Pharma Recent Development Table 143. North America Drug-Device Combination Products Revenue by Type (2021-2026) & (US$ Million) Table 144. North America Drug-Device Combination Products Revenue by Type (2027-2032) & (US$ Million) Table 145. North America Drug-Device Combination Products Revenue by Application (2021-2026) & (US$ Million) Table 146. North America Drug-Device Combination Products Revenue by Application (2027-2032) & (US$ Million) Table 147. North America Drug-Device Combination Products Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 148. North America Drug-Device Combination Products Revenue by Country (2021-2026) & (US$ Million) Table 149. North America Drug-Device Combination Products Revenue by Country (US$ Million) & (2027-2032) Table 150. Europe Drug-Device Combination Products Revenue by Type (2021-2026) & (US$ Million) Table 151. Europe Drug-Device Combination Products Revenue by Type (2027-2032) & (US$ Million) Table 152. Europe Drug-Device Combination Products Revenue by Application (2021-2026) & (US$ Million) Table 153. Europe Drug-Device Combination Products Revenue by Application (2027-2032) & (US$ Million) Table 154. Europe Drug-Device Combination Products Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 155. Europe Drug-Device Combination Products Revenue by Country (2021-2026) & (US$ Million) Table 156. Europe Drug-Device Combination Products Revenue by Country (US$ Million) & (2027-2032) Table 157. China Drug-Device Combination Products Revenue by Type (2021-2026) & (US$ Million) Table 158. China Drug-Device Combination Products Revenue by Type (2027-2032) & (US$ Million) Table 159. China Drug-Device Combination Products Revenue by Application (2021-2026) & (US$ Million) Table 160. China Drug-Device Combination Products Revenue by Application (2027-2032) & (US$ Million) Table 161. Asia Drug-Device Combination Products Revenue by Type (2021-2026) & (US$ Million) Table 162. Asia Drug-Device Combination Products Revenue by Type (2027-2032) & (US$ Million) Table 163. Asia Drug-Device Combination Products Revenue by Application (2021-2026) & (US$ Million) Table 164. Asia Drug-Device Combination Products Revenue by Application (2027-2032) & (US$ Million) Table 165. Asia Drug-Device Combination Products Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 166. Asia Drug-Device Combination Products Revenue by Region (US$ Million) & (2021-2026) Table 167. Asia Drug-Device Combination Products Revenue by Region (US$ Million) & (2027-2032) Table 168. SAMEA Drug-Device Combination Products Revenue by Type (2021-2026) & (US$ Million) Table 169. SAMEA Drug-Device Combination Products Revenue by Type (2027-2032) & (US$ Million) Table 170. SAMEA Drug-Device Combination Products Revenue by Application (2021-2026) & (US$ Million) Table 171. SAMEA Drug-Device Combination Products Revenue by Application (2027-2032) & (US$ Million) Table 172. SAMEA Drug-Device Combination Products Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 173. SAMEA Drug-Device Combination Products Revenue by Country (2021-2026) & (US$ Million) Table 174. SAMEA Drug-Device Combination Products Revenue by Country (US$ Million) & (2027-2032) Table 175. Research Programs/Design for This Report Table 176. Authors List of This Report Table 177. Secondary Sources Table 178. Primary Sources List of Figures Figure 1. Drug-Device Combination Products Image Figure 2. Global Drug-Device Combination Products Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drug-Device Combination Products Market Size Share 2021 VS 2025 VS 2032 Figure 4. Drug-Coated Device Image Figure 5. Prefilled Drug Delivery Systems Image Figure 6. Nebulizer and Inhaler Image Figure 7. Transdermal Delivery System Image Figure 8. Others Image Figure 9. Global Drug-Device Combination Products Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Drug-Device Combination Products Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospital andClinic Image Figure 12. Retail Pharmacies Image Figure 13. Other Image Figure 14. Global Drug-Device Combination Products Market Size (US$ Million) & (2021-2032) Figure 15. Global Drug-Device Combination Products Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Drug-Device Combination Products Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Drug-Device Combination Products Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Drug-Device Combination Products Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Drug-Device Combination Products Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Drug-Device Combination Products Revenue Market Share by Type (2021-2032) Figure 22. Global Drug-Device Combination Products Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Drug-Device Combination Products Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Drug-Device Combination Products Revenue Market Share by Application (2021-2032) Figure 25. North America Drug-Device Combination Products Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Drug-Device Combination Products Revenue Share by Type (2021-2032) Figure 27. North America Drug-Device Combination Products Revenue Share by Application (2021-2032) Figure 28. North America Drug-Device Combination Products Revenue Share by Country (2021-2032) Figure 29. United States Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Drug-Device Combination Products Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Drug-Device Combination Products Revenue Share by Type (2021-2032) Figure 34. Europe Drug-Device Combination Products Revenue Share by Application (2021-2032) Figure 35. Europe Drug-Device Combination Products Revenue Share by Country (2021-2032) Figure 36. Germany Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Drug-Device Combination Products Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Drug-Device Combination Products Revenue Share by Type (2021-2032) Figure 46. China Drug-Device Combination Products Revenue Share by Application (2021-2032) Figure 47. Asia Drug-Device Combination Products Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Drug-Device Combination Products Revenue Share by Type (2021-2032) Figure 49. Asia Drug-Device Combination Products Revenue Share by Application (2021-2032) Figure 50. Asia Drug-Device Combination Products Revenue Share by Region (2021-2032) Figure 51. Japan Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Drug-Device Combination Products Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Drug-Device Combination Products Revenue Share by Type (2021-2032) Figure 59. SAMEA Drug-Device Combination Products Revenue Share by Application (2021-2032) Figure 60. SAMEA Drug-Device Combination Products Revenue Share by Country (2021-2032) Figure 61. Brazil Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Drug-Device Combination Products Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Drug-Coated Device
  • Prefilled Drug Delivery Systems
  • Nebulizer and Inhaler
  • Transdermal Delivery System
  • Others
Applications
  • Hospital andClinic
  • Retail Pharmacies
  • Other
Companies covered
  • GSK
  • Novo Nordisk
  • Eli Lilly
  • AstraZeneca
  • Sanofi
  • Boston Scientific
  • Abbott
  • Boehringer Ingelheim
  • Medtronic
  • Mylan
  • 3M
  • Hisamitsu
  • Smith & Nephew
  • Molnlycke
  • Teleflex
  • BD
  • Lepu Medical
  • MicroPort
  • Terumo
  • B. Braun
  • Antares Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Drug-Device Combination Products Market by Type
  3. 1.2.1 Global Drug-Device Combination Products Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Drug-Coated Device
  5. 1.2.3 Prefilled Drug Delivery Systems
  6. 1.2.4 Nebulizer and Inhaler
  7. 1.2.5 Transdermal Delivery System
  8. 1.2.6 Others
  9. 1.3 Drug-Device Combination Products Market by Application
  10. 1.3.1 Global Drug-Device Combination Products Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospital andClinic
  12. 1.3.3 Retail Pharmacies
  13. 1.3.4 Other
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Drug-Device Combination Products Market Dynamics
  1. 2.1 Drug-Device Combination Products Industry Trends
  2. 2.2 Drug-Device Combination Products Industry Drivers
  3. 2.3 Drug-Device Combination Products Industry Opportunities and Challenges
  4. 2.4 Drug-Device Combination Products Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Drug-Device Combination Products Market Perspective (2021-2032)
  2. 3.2 Global Drug-Device Combination Products Growth Trends by Region
  3. 3.2.1 Global Drug-Device Combination Products Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Drug-Device Combination Products Market Size by Region (2021-2026)
  5. 3.2.3 Global Drug-Device Combination Products Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Drug-Device Combination Products Revenue by Players
  2. 4.1.1 Global Drug-Device Combination Products Revenue by Players (2021-2026)
  3. 4.1.2 Global Drug-Device Combination Products Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Drug-Device Combination Products Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Drug-Device Combination Products Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Drug-Device Combination Products Key Players Headquarters & Area Served
  7. 4.4 Global Drug-Device Combination Products Players, Product Type & Application
  8. 4.5 Global Drug-Device Combination Products Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Drug-Device Combination Products Market CR5 and HHI
  11. 4.6.3 2025 Drug-Device Combination Products Tier 1, Tier 2, and Tier 3
5 Drug-Device Combination Products Market Size by Type
  1. 5.1 Global Drug-Device Combination Products Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Drug-Device Combination Products Revenue by Type (2021-2032)
  3. 5.3 Global Drug-Device Combination Products Revenue Market Share by Type (2021-2032)
6 Drug-Device Combination Products Market Size by Application
  1. 6.1 Global Drug-Device Combination Products Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Drug-Device Combination Products Revenue by Application (2021-2032)
  3. 6.3 Global Drug-Device Combination Products Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 GSK
  2. 7.1.1 GSK Company Information
  3. 7.1.2 GSK Business Overview
  4. 7.1.3 GSK Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  5. 7.1.4 GSK Drug-Device Combination Products Product Portfolio
  6. 7.1.5 GSK Recent Developments
  7. 7.2 Novo Nordisk
  8. 7.2.1 Novo Nordisk Company Information
  9. 7.2.2 Novo Nordisk Business Overview
  10. 7.2.3 Novo Nordisk Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novo Nordisk Drug-Device Combination Products Product Portfolio
  12. 7.2.5 Novo Nordisk Recent Developments
  13. 7.3 Eli Lilly
  14. 7.3.1 Eli Lilly Company Information
  15. 7.3.2 Eli Lilly Business Overview
  16. 7.3.3 Eli Lilly Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Eli Lilly Drug-Device Combination Products Product Portfolio
  18. 7.3.5 Eli Lilly Recent Developments
  19. 7.4 AstraZeneca
  20. 7.4.1 AstraZeneca Company Information
  21. 7.4.2 AstraZeneca Business Overview
  22. 7.4.3 AstraZeneca Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  23. 7.4.4 AstraZeneca Drug-Device Combination Products Product Portfolio
  24. 7.4.5 AstraZeneca Recent Developments
  25. 7.5 Sanofi
  26. 7.5.1 Sanofi Company Information
  27. 7.5.2 Sanofi Business Overview
  28. 7.5.3 Sanofi Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Sanofi Drug-Device Combination Products Product Portfolio
  30. 7.5.5 Sanofi Recent Developments
  31. 7.6 Boston Scientific
  32. 7.6.1 Boston Scientific Company Information
  33. 7.6.2 Boston Scientific Business Overview
  34. 7.6.3 Boston Scientific Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Boston Scientific Drug-Device Combination Products Product Portfolio
  36. 7.6.5 Boston Scientific Recent Developments
  37. 7.7 Abbott
  38. 7.7.1 Abbott Company Information
  39. 7.7.2 Abbott Business Overview
  40. 7.7.3 Abbott Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Abbott Drug-Device Combination Products Product Portfolio
  42. 7.7.5 Abbott Recent Developments
  43. 7.8 Boehringer Ingelheim
  44. 7.8.1 Boehringer Ingelheim Company Information
  45. 7.8.2 Boehringer Ingelheim Business Overview
  46. 7.8.3 Boehringer Ingelheim Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Boehringer Ingelheim Drug-Device Combination Products Product Portfolio
  48. 7.8.5 Boehringer Ingelheim Recent Developments
  49. 7.9 Medtronic
  50. 7.9.1 Medtronic Company Information
  51. 7.9.2 Medtronic Business Overview
  52. 7.9.3 Medtronic Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Medtronic Drug-Device Combination Products Product Portfolio
  54. 7.9.5 Medtronic Recent Developments
  55. 7.10 Mylan
  56. 7.10.1 Mylan Company Information
  57. 7.10.2 Mylan Business Overview
  58. 7.10.3 Mylan Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Mylan Drug-Device Combination Products Product Portfolio
  60. 7.10.5 Mylan Recent Developments
  61. 7.11 3M
  62. 7.11.1 3M Company Information
  63. 7.11.2 3M Business Overview
  64. 7.11.3 3M Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  65. 7.11.4 3M Drug-Device Combination Products Product Portfolio
  66. 7.11.5 3M Recent Developments
  67. 7.12 Hisamitsu
  68. 7.12.1 Hisamitsu Company Information
  69. 7.12.2 Hisamitsu Business Overview
  70. 7.12.3 Hisamitsu Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Hisamitsu Drug-Device Combination Products Product Portfolio
  72. 7.12.5 Hisamitsu Recent Developments
  73. 7.13 Smith & Nephew
  74. 7.13.1 Smith & Nephew Company Information
  75. 7.13.2 Smith & Nephew Business Overview
  76. 7.13.3 Smith & Nephew Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Smith & Nephew Drug-Device Combination Products Product Portfolio
  78. 7.13.5 Smith & Nephew Recent Developments
  79. 7.14 Molnlycke
  80. 7.14.1 Molnlycke Company Information
  81. 7.14.2 Molnlycke Business Overview
  82. 7.14.3 Molnlycke Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Molnlycke Drug-Device Combination Products Product Portfolio
  84. 7.14.5 Molnlycke Recent Developments
  85. 7.15 Teleflex
  86. 7.15.1 Teleflex Company Information
  87. 7.15.2 Teleflex Business Overview
  88. 7.15.3 Teleflex Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Teleflex Drug-Device Combination Products Product Portfolio
  90. 7.15.5 Teleflex Recent Developments
  91. 7.16 BD
  92. 7.16.1 BD Company Information
  93. 7.16.2 BD Business Overview
  94. 7.16.3 BD Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  95. 7.16.4 BD Drug-Device Combination Products Product Portfolio
  96. 7.16.5 BD Recent Developments
  97. 7.17 Lepu Medical
  98. 7.17.1 Lepu Medical Company Information
  99. 7.17.2 Lepu Medical Business Overview
  100. 7.17.3 Lepu Medical Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Lepu Medical Drug-Device Combination Products Product Portfolio
  102. 7.17.5 Lepu Medical Recent Developments
  103. 7.18 MicroPort
  104. 7.18.1 MicroPort Company Information
  105. 7.18.2 MicroPort Business Overview
  106. 7.18.3 MicroPort Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  107. 7.18.4 MicroPort Drug-Device Combination Products Product Portfolio
  108. 7.18.5 MicroPort Recent Developments
  109. 7.19 Terumo
  110. 7.19.1 Terumo Company Information
  111. 7.19.2 Terumo Business Overview
  112. 7.19.3 Terumo Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Terumo Drug-Device Combination Products Product Portfolio
  114. 7.19.5 Terumo Recent Developments
  115. 7.20 B. Braun
  116. 7.20.1 B. Braun Company Information
  117. 7.20.2 B. Braun Business Overview
  118. 7.20.3 B. Braun Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  119. 7.20.4 B. Braun Drug-Device Combination Products Product Portfolio
  120. 7.20.5 B. Braun Recent Developments
  121. 7.21 Antares Pharma
  122. 7.21.1 Antares Pharma Company Information
  123. 7.21.2 Antares Pharma Business Overview
  124. 7.21.3 Antares Pharma Drug-Device Combination Products Revenue and Gross Margin (2021-2026)
  125. 7.21.4 Antares Pharma Drug-Device Combination Products Product Portfolio
  126. 7.21.5 Antares Pharma Recent Developments
8 North America
  1. 8.1 North America Drug-Device Combination Products Revenue (2021-2032)
  2. 8.2 North America Drug-Device Combination Products Revenue by Type (2021-2032)
  3. 8.2.1 North America Drug-Device Combination Products Revenue by Type (2021-2026)
  4. 8.2.2 North America Drug-Device Combination Products Revenue by Type (2027-2032)
  5. 8.3 North America Drug-Device Combination Products Revenue Share by Type (2021-2032)
  6. 8.4 North America Drug-Device Combination Products Revenue by Application (2021-2032)
  7. 8.4.1 North America Drug-Device Combination Products Revenue by Application (2021-2026)
  8. 8.4.2 North America Drug-Device Combination Products Revenue by Application (2027-2032)
  9. 8.5 North America Drug-Device Combination Products Revenue Share by Application (2021-2032)
  10. 8.6 North America Drug-Device Combination Products Revenue by Country
  11. 8.6.1 North America Drug-Device Combination Products Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Drug-Device Combination Products Revenue by Country (2021-2026)
  13. 8.6.3 North America Drug-Device Combination Products Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Drug-Device Combination Products Revenue (2021-2032)
  2. 9.2 Europe Drug-Device Combination Products Revenue by Type (2021-2032)
  3. 9.2.1 Europe Drug-Device Combination Products Revenue by Type (2021-2026)
  4. 9.2.2 Europe Drug-Device Combination Products Revenue by Type (2027-2032)
  5. 9.3 Europe Drug-Device Combination Products Revenue Share by Type (2021-2032)
  6. 9.4 Europe Drug-Device Combination Products Revenue by Application (2021-2032)
  7. 9.4.1 Europe Drug-Device Combination Products Revenue by Application (2021-2026)
  8. 9.4.2 Europe Drug-Device Combination Products Revenue by Application (2027-2032)
  9. 9.5 Europe Drug-Device Combination Products Revenue Share by Application (2021-2032)
  10. 9.6 Europe Drug-Device Combination Products Revenue by Country
  11. 9.6.1 Europe Drug-Device Combination Products Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Drug-Device Combination Products Revenue by Country (2021-2026)
  13. 9.6.3 Europe Drug-Device Combination Products Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Drug-Device Combination Products Revenue (2021-2032)
  2. 10.2 China Drug-Device Combination Products Revenue by Type (2021-2032)
  3. 10.2.1 China Drug-Device Combination Products Revenue by Type (2021-2026)
  4. 10.2.2 China Drug-Device Combination Products Revenue by Type (2027-2032)
  5. 10.3 China Drug-Device Combination Products Revenue Share by Type (2021-2032)
  6. 10.4 China Drug-Device Combination Products Revenue by Application (2021-2032)
  7. 10.4.1 China Drug-Device Combination Products Revenue by Application (2021-2026)
  8. 10.4.2 China Drug-Device Combination Products Revenue by Application (2027-2032)
  9. 10.5 China Drug-Device Combination Products Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Drug-Device Combination Products Revenue (2021-2032)
  2. 11.2 Asia Drug-Device Combination Products Revenue by Type (2021-2032)
  3. 11.2.1 Asia Drug-Device Combination Products Revenue by Type (2021-2026)
  4. 11.2.2 Asia Drug-Device Combination Products Revenue by Type (2027-2032)
  5. 11.3 Asia Drug-Device Combination Products Revenue Share by Type (2021-2032)
  6. 11.4 Asia Drug-Device Combination Products Revenue by Application (2021-2032)
  7. 11.4.1 Asia Drug-Device Combination Products Revenue by Application (2021-2026)
  8. 11.4.2 Asia Drug-Device Combination Products Revenue by Application (2027-2032)
  9. 11.5 Asia Drug-Device Combination Products Revenue Share by Application (2021-2032)
  10. 11.6 Asia Drug-Device Combination Products Revenue by Country
  11. 11.6.1 Asia Drug-Device Combination Products Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Drug-Device Combination Products Revenue by Country (2021-2026)
  13. 11.6.3 Asia Drug-Device Combination Products Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Drug-Device Combination Products Revenue (2021-2032)
  2. 12.2 SAMEA Drug-Device Combination Products Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Drug-Device Combination Products Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Drug-Device Combination Products Revenue by Type (2027-2032)
  5. 12.3 SAMEA Drug-Device Combination Products Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Drug-Device Combination Products Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Drug-Device Combination Products Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Drug-Device Combination Products Revenue by Application (2027-2032)
  9. 12.5 SAMEA Drug-Device Combination Products Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Drug-Device Combination Products Revenue by Country
  11. 12.6.1 SAMEA Drug-Device Combination Products Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Drug-Device Combination Products Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Drug-Device Combination Products Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst